1316216-05-3Relevant articles and documents
Mercapto compounds as histone deacetylase inhibitors and uses thereof
-
Paragraph 0095; 0102-0104; 0127-0130, (2020/03/29)
Experimental results show, that the compound shown by the invention has high blood-brain barrier permeability, on normal cytotoxic low, potential cardiac toxicity, and higher blood-brain barrier permeability of, on a cell model as a compound shown, or a pharmaceutically acceptable salt, ester or a prodrug, of the compound as a high-efficiency low-toxicity anti-tumor or neurodegenerative disease therapeutic agent shown in the invention. The compound has high blood-brain barrier permeability . The compound of the present invention has higher blood-brain barrier permeability as shown in the development prospect (I) of, a: therapeutic agent for high-efficiency and low-toxicity antitumor or neurodegenerative diseases.
METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND CD20 INHIBITORY ANTIBODIES
-
Paragraph 0278; 0281; 0282, (2018/03/01)
The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also provided herein are methods for treatin
PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF
-
Page/Page column 30; 31, (2018/06/12)
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.